Evidence map›Paper›PMID 29669885›Full record

ArticlemSphere2018

The Heteroaryldihydropyrimidine Bay 38-7690 Induces Hepatitis B Virus Core Protein Aggregates Associated with Promyelocytic Leukemia Nuclear Bodies in Infected Cells.

Andrew D Huber, Jennifer J Wolf, Dandan Liu, Anna T Gres, Jing Tang, Kelsey N Boschert, Maritza N Puray-Chavez, Dallas L Pineda, Thomas G Laughlin, Emily M Coonrod and 5 more

Open access · goldAbstract read
In one paragraph

Article in mSphere, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Andrew D HuberChristopher S. Bond Life Sciences Center, University of Missouri, Columbia, Missouri, USA.
Jennifer J WolfChristopher S. Bond Life Sciences Center, University of Missouri, Columbia, Missouri, USA.
Dandan LiuChristopher S. Bond Life Sciences Center, University of Missouri, Columbia, Missouri, USA.
Anna T GresChristopher S. Bond Life Sciences Center, University of Missouri, Columbia, Missouri, USA.
Jing TangCenter for Drug Design, Academic Health Center, University of Minnesota, Minneapolis, Minnesota, USA.
Kelsey N BoschertChristopher S. Bond Life Sciences Center, University of Missouri, Columbia, Missouri, USA.
Maritza N Puray-ChavezChristopher S. Bond Life Sciences Center, University of Missouri, Columbia, Missouri, USA.
Dallas L PinedaChristopher S. Bond Life Sciences Center, University of Missouri, Columbia, Missouri, USA.
Thomas G LaughlinChristopher S. Bond Life Sciences Center, University of Missouri, Columbia, Missouri, USA.
Emily M CoonrodChristopher S. Bond Life Sciences Center, University of Missouri, Columbia, Missouri, USA.
Qiongying YangChristopher S. Bond Life Sciences Center, University of Missouri, Columbia, Missouri, USA.
Juan JiChristopher S. Bond Life Sciences Center, University of Missouri, Columbia, Missouri, USA.
Karen A KirbyChristopher S. Bond Life Sciences Center, University of Missouri, Columbia, Missouri, USA.
Zhengqiang WangCenter for Drug Design, Academic Health Center, University of Minnesota, Minneapolis, Minnesota, USA.
Stefan G SarafianosChristopher S. Bond Life Sciences Center, University of Missouri, Columbia, Missouri, USA ssarafi@emory.edu.
University of Missouri · USUniversity of Minnesota · US

Funding

Novel antivirals targeting the RNase H activity of HIV reverse transcriptaseR01AI100890 · NIAID · UNIVERSITY OF MISSOURI-COLUMBIA · PI SARAFIANOS, STEFAN G, WANG, ZHENGQIANG · 2012 to 2016
$3.6M
Taking aim at HBV eradication using novel NRTIs and Capsid effectorsR01AI121315 · NIAID · UNIVERSITY OF MISSOURI-COLUMBIA · PI SARAFIANOS, STEFAN G, WANG, ZHENGQIANG · 2016 to 2020
$3.0M
NIAID NIH HHS R01 AI100890NIAID NIH HHS R01 AI121315
6 · The paper itself

Abstract

Heteroaryldihydropyrimidines (HAPs) are compounds that inhibit hepatitis B virus (HBV) replication by modulating viral capsid assembly. While their biophysical effects on capsid assembly

Indexed as

Antiviral AgentsCapsidCapsid ProteinsFluorescent Antibody TechniqueHepatitis BHepatitis B virusHep G2 CellsHumansInclusion Bodies, ViralProtein AggregatesPyridinesPyrimidinesRecombinant ProteinsVirus AssemblyVirus ReplicationAntiviral AgentsBAY 38-7690Capsid ProteinsProtein AggregatesPyridinesPyrimidinesRecombinant Proteinsantiviral agentscapsidhepatitis B virusmechanisms of actionvirologyvirus-host interactions

Identifiers

PMID29669885
PMCPMC5907649
OpenAlexW2801744044

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.